MaxCyte Inc（MXCT）股票分析

AI 分析 of MaxCyte Inc (MXCT)

持有

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.

估值指標

MaxCyte Inc（MXCT）目前預期本益比為 0.00，5 年平均預期本益比為 -13.28。

預期本益比

高估

5 年均值 P/E

-13.28

目前P/E

0.00

高估

-3.68

低估

-22.87

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-9.98

目前EV/EBITDA

-3.07

高估

1.46

低估

-21.43

預期股價營收比

低估

5 年均值 P/S

9.43

目前P/S

3.86

高估

14.36

低估

4.49

Alphio AI 對 MXCT 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%MXCT

$2.88

情境價格

基

基準

基準 · 50%MXCT

$2.21

情境價格

悲

悲觀

悲觀 · 25%MXCT

$1.63

情境價格

持有 MXCT 的大戶

A

Apollo Global Management, Inc.

+ 持有MXCT

-2.44%

3個月報酬率

MXCT 常見問題 —— 由 Alphio AI 解答

MaxCyte, Inc. is a cell-engineering focused company providing solutions to advance the discovery, development and commercialization of cell therapeutics. It leverages its cell engineering technology platform to enable the programs of its biotechnology and pharmaceutical company customers who are engaged in cell therapy. Its ExPERT platform, which is based on its Flow Electroporation technology, is designed to support the expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes four instruments, the ATx, STx, GTx and VLx; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a worldwide intellectual property portfolio. It also provides comprehensive off-target risk assessment solutions for gene editing, through ONE-seq and GUIDE-seq platforms. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

MaxCyte Inc is currently trading at $1.45, which is 69.4% of its 52-week range, indicating it is closer to its high of $1.80 than its low of $0.64. However, the RSI is at 45.41, suggesting that the stock is neither overbought nor oversold. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a gross margin of 63.86%, which is relatively strong. The main risk is the negative net income reported, with a loss of $8.87 million in Q2 2026, indicating ongoing financial struggles. Therefore, while there are some positive indicators, the overall financial performance and lack of clear upward momentum suggest holding rather than buying right now.